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Abstract
© Bionika Media Ltd. Objective. To investigate vitamin D (VD) levels in women with various
forms of benign breast diseases (BBD) in relation to their clinical features, as well as the impact
of CYP2R1 rs2060793 polymorphism on the level of VD. Subjects and methods. Genotyping for
the locus -1559 T>C gene CYP2R1 (rs2060793) was carried out by realtime polymerase chain
reaction in 247 women (131 healthy individuals and 116 patients with BBD). The level of VD was
estimated  by  chemiluminescence  immunoassay  in  100  patients  with  BBD and  75  healthy
women. Results. 88% of the patients with BBD had a low blood VD level while 53% of them had
VD deficiency that correlated with the severity of the disease. The lowest VD provision among
the healthy women is characteristic of homozygous carriers of C alleles in the CYP2R1 gene. The
patients with BBD had a persistent VD deficient state, regardless of the variant of CYP2R1 gene
polymorphism. Conclusion. VD deficiency in women with BBD has a direct impact on the clinical
symptoms of the disease and is unassociated with the genetic polymorphism in the CYP2R1
gene.
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